Clement Chan, MD, Ophthalmology, Palm Desert, CA


Ophthalmology Palm Desert, CA

Retinal Disease

President and Medical Director

Dr. Chan is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Chan's full profile

Already have an account?

Education & Training

  • Charles Retina Institute Post-fellowship elective, 1995 - 1996
  • Washington University - Barnes-Jewish HospitalFellowship, Vitreoretinal ophthalmology, 1994 - 1995
  • Loma Linda UniversityResidency, Ophthalmology, 1981 - 1984
  • White Memorial Medical CenterInternship, Transitional Year, 1980 - 1981
  • Loma Linda University School of MedicineClass of 1980
  • Pacific Union CollegeB.S., Biochemistry, Magna Cum Laude, 1973 - 1977

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1981 - 2023
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Clinical Professor, Clinician Scientist School of Medicine, Loma Linda University, Loma Linda, California, 2016
  • Regional Top Doctor Castle Connolly, 2014
  • Nomination American Ophthalmological Society (AOS), 2013
  • Join now to see all

Clinical Trials

Publications & Presentations


Journal Articles

  • Prospective Evaluation of the Incidence and Risk Factors for the Development of RPE Tears after High-and Low-dose Ranibizumab Therapy  
    Sarraf D, Chan CK, Rahimy E, Abraham P, Retina, 1/1/2013
  • Exploratory Analysis of Effect of Intravitreal Ranibizumab or Triamcinolone on Worsening of Diabetic Retinopathy in a Randomized Clinical Trial  
    Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG, Stone T, for the Diabetic Retinopathy Clinical Research Network, JAMA Ophthalmol, 1/1/2013
  • Response to the Letter by Talks Et Al (June 27, 2012) On High-dose Ranibizumab Therapy for Vascularized Pigment Epithelial Detachment  
    Chan CK, Sarraf D, EYE: Advance Online Publication, 10/19/2012
  • Join now to see all

Books/Book Chapters

  • Join now to see all


  • Results at Six Months after Conversion to Aflibercept for Patients on Prior Ranibizumab or Bevacizumab Treatment for Exudative Age-Related Macular Degeneration
    Chan CK, Jain A, Sadda S, Varshney N, Session 383, CNV Management, ARVO Annual Meeting: Leading Eye and Vision Research, Orlando Convention Center, Orlando, FL, 5/6/2014
  • The EVEN Study: An In-depth Prospective Trial on Intravitreal Aflibercept Treatment of Submacular Vascularized Pigment Epithelial Detachment
    Lalezary M, Sarraf D, Abraham P, Lin SG, Chan CK, Session 383, CNV Management, ARVO Annual Meeting: Leading Eye and Vision Research, Orlando Convention Center, Orlando, FL, 5/6/2014
  • Pneumatic Maculopexy: A Novel Approach for Treatment of Symptomatic Vitreomacular Traction
    Mein C, Chan CK, Session 110, Vitreomacular Interface and Management, ARVO Annual Meeting: Leading Eye and Vision Research, Orlando Convention Center, Orlando, FL, 5/4/2014
  • Join now to see all


  • Comparison of Visual and OCT Outcomes in Eyes with and without Prior Vitrectomy Receiving Anti-VEGF Therapy in a Randomized Trial on Ranibizumab Prompt or Deferred Las... 
    Kongresshaus, Zurich, Switzerland - 9/5/2014
  • Pharmacodynamic and Pharmacokinetic Profile of Intraocular Aflibercept (Eylea) in Patients with Neovascular AMD Receiving Intravitreal Aflibercept Therapy 
    Kongresshaus, Zurich, Switzerland - 9/4/2014
  • Gas Injection for Vitreomacular Traction in the Era of Pharmacologic Vitreolysis, a Case Report 
    Kongresshaus, Zurich, Switzerland - 9/3/2014
  • Join now to see all

Press Mentions

  • Biologists Design a Plug-and-Play Controller for Gene Expression
    Biologists Design a Plug-and-Play Controller for Gene ExpressionJuly 11th, 2019

Professional Memberships

Other Languages

  • Chinese (Cantonese)